EUCTR2004-004082-15-IT进行中（未招募）不适用
A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCITE (CITARABINE LIPOSOMIALE INJECTON) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPOBLASTIC LEUKEMIA OR VERY RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR VERY AGGRESSIVE LYMPOMA
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2007年7月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCYTE® (CYTARABINE LIPOSOME INJECTION) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH-GRADE LYMPHOMA - DepoCyte® in ALL / NHL CNS relapseAcute lymphoblastic leukaemiaEUCTR2005-000173-21-ATDieter Hoelzer, MD,PhD20
已完成
2 期
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
进行中（未招募）
不适用
MK-5172 + MK-8742 in HCV-infected subjects with hepatic insufficiency (CP-B)MedDRA version: 17.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-000672-25-EEMerck Sharp & Dohme Corp., a subsidary of Merck & Co.103
进行中（未招募）
不适用
MK-5172 + MK-8742 in HCV-infected subjects with hepatic insufficiency (CP-B)MedDRA version: 17.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-000672-25-PLMerck Sharp & Dohme Copr., a subsidary of Merck & Co.100
进行中（未招募）
1 期
MK-5172 + MK-8742 in HCV-infected subjects with hepatic insufficiency (CP-B)MedDRA version: 18.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-000672-25-GBMerck Sharp & Dohme Corp., a subsidary of Merck & Co.103